Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 72

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 72
---
     | 01/03/2024 |     |                                           | 268,560 |     | $                                     | 20.33 |     | $                                  | 3,405,851 |     |                                                                                                                                                                                                                                                                                    | 2.1 | % |
| Alexander O. Schuth, M.D. |     | 01/03/2024 |     |                                           | 161,160 |     | $                                     | 20.33 |     | $                                  | 2,043,815 |     |                                                                                                                                                                                                                                                                                    | 2.1 | % |
| Carole Ho, M.D.           |     | 01/03/2024 |     |                                           | 161,160 |     | $                                     | 20.33 |     | $                                  | 2,043,815 |     |                                                                                                                                                                                                                                                                                    | 2.1 | % |

(1) Calculated using the closing price of our common stock on NASDAQ on January 5, 2024 and January 9, 2024, of $19.34 and $19.74, per share, respectively.

<div align='center'>-54-</div>

### DIRECTOR COMPENSATION
Each non-employee director is eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards under our outside director compensation policy, which was originally adopted in November 2017 and became effective in connection with the initial public offering of our securities in December 2017. Our outside director compensation policy was crafted in consultation with Aon, an independent consultant, in anticipation of our initial public offering. Aon provided us with competitive data, analysis and recommendations regarding non-employee director compensation. After careful consideration of this information and the scope of the duties and responsibilities of our non-employee directors, our board of directors approved our outside director compensation policy, which we believe provides reasonable compensation to our non-employee directors that is commensurate with their contributions and appropriately aligned with our peers. Our outside director compensation policy has been amended periodically, most recently in January 2025. We also reimburse our directors for expenses associated with attending meetings of our board of directors and committees of our board of directors.

Pursuant to our amended outside director compensation policy, all non-employee directors (also referred to as "outside directors") were paid cash compensation as set forth below during the year ended December 31, 2024. The cash compensation our outside directors are entitled to receive for their services for